Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children.
Bougouma EC, Palacpac NMQ, Tiono AB, Nebie I, Ouédraogo A, Houard S, Yagi M, Coulibaly SA, Diarra A, Tougan T, Ouedraogo AZ, Soulama I, Arisue N, Yaro JB, D'Alessio F, Leroy O, Cousens S, Horii T, Sirima SB.
Bougouma EC, et al. Among authors: cousens s.
Front Immunol. 2022 Aug 31;13:978591. doi: 10.3389/fimmu.2022.978591. eCollection 2022.
Front Immunol. 2022.
PMID: 36119062
Free PMC article.
Clinical Trial.